Synthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agents.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 05 2019
Historique:
received: 17 12 2018
revised: 23 03 2019
accepted: 06 04 2019
pubmed: 15 4 2019
medline: 23 2 2020
entrez: 15 4 2019
Statut: ppublish

Résumé

A series of bi-functional 7-hydroxycoumarin platinum(IV) complexes were synthesized, characterized, and evaluated for antitumor activities. The 7-hydroxycoumarin platinum(IV) complexes display moderate to effective antitumor activities toward the tested cell lines and show much potential in overcoming drug resistance of platinum(II) drugs. In reducing microenvironment, the title compounds could be reduced to platinum(II) complex accompanied with two equivalents of coumarin units. By a unique mechanism, the 7-hydroxycoumarin platinum(IV) complex attacks DNA via the released platinum(II) compound, meanwhile it also inhibits the activities of cyclooxygenase by coumarin fragment. This action mechanism might be of much benefit for reducing tumor-related inflammation in the progress of inhibiting tumor proliferation and overcoming cisplatin resistance. The incorporation of 7-hydroxycoumarin leads to significantly enhanced platinum accumulation in both whole tumor cells and DNA. The HSA interaction investigation reveals that the tested coumarin platinum(IV) compound could effectively combine with HSA via van der Waals force and hydrogen bond.

Identifiants

pubmed: 30981607
pii: S0968-0896(18)32106-0
doi: 10.1016/j.bmc.2019.04.009
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Coordination Complexes 0
Serum Albumin 0
Umbelliferones 0
Platinum 49DFR088MY
7-hydroxycoumarin 60Z60NTL4G
Cyclooxygenase 2 EC 1.14.99.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2112-2121

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Qingpeng Wang (Q)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China. Electronic address: lywqp@126.com.

Yan Chen (Y)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China.

Guoshuai Li (G)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China.

Zhifang Liu (Z)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China.

Jing Ma (J)

Institute of Chemical Biology, College of Pharmacy, Henan University, Kaifeng 475004, China.

Min Liu (M)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China.

Dacheng Li (D)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China; Shandong Provincial Key Laboratory of Chemical Energy Storage and Novel Cell Technology, Liaocheng University, Liaocheng 252059, China. Electronic address: lidacheng62@163.com.

Jun Han (J)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China.

Bingquan Wang (B)

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH